Elafibranor(Elafibranor) - 药物靶点：PPARα x PPARδ_在研适应症：原发性胆汁性胆管炎，原发性硬化性胆管炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Elafibranor (USAN)、GFT-505、IQIRVO

+ [1]

靶点

PPARα x PPARδ

作用方式

激动剂

作用机制

PPARα激动剂(过氧化物酶体增长因子活化受体α激动剂)、PPARδ激动剂(过氧化物酶体增殖物激活受体δ激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Ipsen SAIpsen Pharma SAIpsen Korea Ltd.

+ [4]

非在研机构

Terns Pharmaceuticals, Inc.

权益机构

Ipsen SA

Terns Pharmaceuticals, Inc.

Healthcare Royalty Management LLC

+ [1]

最高研发阶段批准上市

首次获批日期

美国 (2024-06-10),

原发性胆汁性胆管炎

最高研发阶段(中国)终止

特殊审评优先审评 (美国)、突破性疗法 (美国)、快速通道 (美国)、加速批准 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (韩国)、孤儿药 (日本)

登录后查看时间轴

结构/序列

分子式C22H24O4S

InChIKeyAFLFKFHDSCQHOL-UHFFFAOYSA-N

CAS号824932-88-9

关联

24

项与 Elafibranor 相关的临床试验

NCT06730061

/ Recruiting临床3期

A Phase III, Open-label, Single Arm Study to Investigate the Efficacy and Safety of Elafibranor 80 mg in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)

The purpose of this study is to find out about the safety and how well the study intervention (elafibranor) works in participants with PBC. The participants in this study will have confirmed PBC with inadequate response or intolerance to UDCA, which is a medication used in the management and treatment of cholestatic liver disease.
PBC is a slowly progressive disease characterised by damage of the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis).
PBC may also be associated with multiple symptoms. Many patients with PBC may require a liver transplant or may die if the disease progresses and a liver transplant is not done. In this study all participants will receive a daily dose of elafibranor (the study intervention).
The main aim of this study is to determine if elafibranor reduces alkaline phosphatase (ALP) and total bilirubin levels. High ALP and bilirubin levels in the blood can indicate liver disease.
There will be 4 periods in this study: A screening period (up to 10 weeks) to assess whether the participant can take part. A treatment period (52 weeks) where all eligible participants will receive elafibranor. A variable treatment extension period (2-5 years) from End Of Treatment (EOT) period up to the commercial availability of elafibranor in Japan. A follow-up period (4 weeks) where participants' health will be monitored.
Participants will undergo blood sampling, urine collections, physical examinations, clinical evaluations, electrocardiograms (ECG: recording of the electrical activity of heart), ultrasound examinations (a non-invasive test that passes a probe over skin to look at the bladder, urinary tract, and liver), and Fibroscan® examinations (to measure stiffness of the liver). They will also be asked to fill in questionnaires. Each participant will be in this study for up to approximately 6 years

开始日期2025-01-16

申办/合作机构

Ipsen SA

NCT06383403

/ Active, not recruiting临床3期

A Phase IIIb Randomised, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm Study to Evaluate the Effect of Elafibranor 80 mg on Normalisation of Alkaline Phosphatase in Adult Participants With Primary Biliary Cholangitis (PBC) and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

The participants in this study will have confirmed PBC with inadequate response or intolerance to Ursodeoxycholic acid (UDCA), which is a medication used in the management and treatment of cholestatic liver disease.
Primary biliary cholangitis is a slowly progressive disease characterised by damage of the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms.
Many patients with PBC may require a liver transplant or may die if the disease progresses and a liver transplant is not done. This study will compare a daily dose of elafibranor (the study drug) to a daily dose of placebo (a dummy treatment).
The main aim of this study is to determine if elafibranor is better than placebo in reducing ALP levels to a normal value. High ALP levels in the blood can indicate liver disease.
There will be three periods in this study: A screening period (up to 8 weeks) to assess whether the participant can take part; a treatment period (up to 52 weeks) where eligible participants will be grouped as per their blood ALP levels and randomly assigned to either receive elafibranor or placebo, and a follow-up period (4 weeks) where participants' health will be monitored.
Participants will be twice as likely to receive elafibranor than placebo (2:1 ratio).
Participants will undergo blood sampling, urine collections, physical examinations, clinical evaluations, electrocardiograms (ECG: recording of the electrical activity of heart), ultrasound examinations (a noninvasive test that passes a probe over skin to look at the bladder, urinary tract, and liver), and Fibroscan® examinations (a noninvasive test that passes a probe on skin to measure stiffness of the liver).
They will also be asked to fill in questionnaires. Each participant will be in this study for up to 64 weeks (15 months).

开始日期2024-07-09

申办/合作机构

Ipsen SA

NCT06016842

/ Recruiting临床3期

A Phase III Randomised, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm Study to Evaluate the Efficacy and Safety of Elafibranor 80 mg on Long-Term Clinical Outcomes in Adult Participants With Primary Biliary Cholangitis (PBC)

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver).
PBC is a slowly progressive disease, characterised by damage to the bile ducts in the liver, leading to a build-up of bile acids which causes further damage.
The liver damage in PBC may lead to cirrhosis. PBC may also be associated with multiple symptoms. Many patients with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not done.
This study will compare a daily dose of elafibranor (the study drug) to a daily dose of placebo (a dummy treatment) and will last up to 3.5 years for each participant.
The main aim of this study is to determine if elafibranor is better than placebo in preventing clinical outcome events showing disease worsening (including progression of disease leading to liver transplant or death).
This study will also study the safety of long-term treatment with elafibranor, as well as the impact on symptoms such as itching and tiredness.

开始日期2023-08-31

申办/合作机构

Ipsen SA

100 项与 Elafibranor 相关的临床结果

登录后查看更多信息

100 项与 Elafibranor 相关的转化医学

登录后查看更多信息

100 项与 Elafibranor 相关的专利（医药）

登录后查看更多信息

142

项与 Elafibranor 相关的文献（医药）

2025-11-01·JOURNAL OF MOLECULAR GRAPHICS & MODELLING

Unveiling the therapeutic potential of artopetelin flavonoids through computational approaches as peroxisome proliferator-activated receptor-delta (PPARδ) agonists

Article

作者: Poudel, Manila ; Parajuli, Nirmal ; Tamang, Ashika ; Bharati, Samjhana ; Maharjan, Binita ; Shrestha, Aakar ; Shrestha, Ram Lal Swagat ; Subin, Jhashanath Adhikari ; Shiva, M C ; Marasini, Bishnu P ; Shrestha, Timila

Diabetes mellitus is a growing global health concern, with peroxisome proliferator-activated receptor-delta (PPARδ) emerging as a promising therapeutic target due to its role in glucose regulation. Flavonoids, a class of plant-derived bioactive compounds, are known for their anti-diabetic properties. The present study aims to explore the potential of artopetelin flavonoids as PPARδ activators using a range of computational approaches. Molecular docking (MD) calculations identified six artopetelin ligands with binding affinities surpassing those of the native ligand (-10.4 kcal/mol) and the reference drugs such as elafibranor (-10.0 kcal/mol) and seladelpar (-9.8 kcal/mol). The highest binding affinity was obtained for artopetelin A, with a value of -11.8 kcal/mol. All candidates, except artopetelin B, were bound at the receptor's catalytic site, suggesting potential for competitive activation. Molecular dynamics simulations (MDS) of the top five complexes revealed structural stability, with consistent root mean square deviation (RMSD) profiles and stable hydrogen bonding patterns. Gibbs free energy changes (ΔG_BFE < 0) confirmed the sustained thermodynamic spontaneity of complex formation reactions where the values ranged from -39.88 to -26.66 kcal/mol. Pharmacokinetic predictions via pkCSM indicated favorable drug-likeness and ADMET profiles. These preliminary in silico findings highlight the strong potential of top five artopetelin flavonoids as PPARδ activators for type 2 diabetes management, underscoring their promise as plant-derived therapeutic agents and warranting further experimental validation.

2025-10-01·HEPATOLOGY

Primary biliary cholangitis: Personalizing second-line therapies

Review

作者: Bowlus, Christopher L. ; Levy, Cynthia

Primary biliary cholangitis (PBC) is an enigmatic, autoimmune disease targeting the small intralobular bile ducts resulting in cholestasis and potentially progression to biliary cirrhosis. Primarily affecting middle-aged women, the diagnosis of PBC is typically straightforward, with most patients presenting with cholestatic liver tests and the highly specific antimitochondrial antibody. For decades, the foundational treatment of PBC has been ursodeoxycholic acid, which delays disease progression in most patients but has no impact on PBC symptoms. Large cohort studies of patients with PBC have established the benefit of maximizing the reduction in serum alkaline phosphatase levels with ursodeoxycholic acid and the need to add second-line agents in patients who do not achieve an adequate response. Advances in the understanding of bile acid physiology have led to the development of new agents that improve cholestasis in patients with PBC and are predicted to reduce the risk of disease progression. Obeticholic acid, the first second-line therapy to be approved for PBC, significantly improves liver biochemistries and has been associated with improved long-term clinical outcomes but is limited by its propensity to induce pruritus. Elafibranor and seladelpar are peroxisome proliferator-activated receptor agonists recently approved for use in patients with PBC, whereas bezafibrate and fenofibrate are available as off-label therapies. They also have shown biochemical improvements among patients with an inadequate response to ursodeoxycholic acid but may improve symptoms of pruritus. Herein, we review the patient features to consider when deciding whether a second-line agent is indicated and which agent to consider for a truly personalized approach to PBC patient care.

2025-07-25·The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

Emerging Therapeutics for Primary Biliary Cholangitis

Review

作者: Cho, Eun Ju

Primary biliary cholangitis (PBC) is an autoimmune liver disease characterized by progressive destruction of the intrahepatic bile ducts, potentially leading to cirrhosis and end-stage liver disease. Ursodeoxycholic acid (UDCA) has been the standard first-line therapy, but up to one-third of patients show an unsatisfactory response to UDCA, underscoring the need for novel treatments. Obeticholic acid is an approved second-line treatment targeting the farnesoid X receptor, but it is associated with adverse effects such as pruritus and the potential risk of hepatic decompensation in patients with advanced disease. Recently, selective peroxisome proliferator-activated receptor (PPAR) agonists, including seladelpar (a PPAR-δ agonist) and elafibranor (dual PPAR-α/δ agonist), have shown substantial efficacy and favorable safety profiles in phase three clinical trials. In addition, emerging therapeutics for symptom relief, such as NOX inhibitors and ileal bile acid transporter inhibitors, further expand the treatment options. These advances offer new opportunities for the improved management of patients with PBC.

266

项与 Elafibranor 相关的新闻（医药）

2025-09-14

·药事纵横

撤市！奥贝胆酸，十年一梦

9月11日，Intercept Pharmaceuticals宣布，应FDA要求，自愿将其肝病药物OCALIVA®（奥贝胆酸）从美国市场撤回。这一决定意味着，这款曾被视为“突破性疗法”的药物，在经历了近十年的起伏后，最终退出美国。图源：Intercept pharma 同时，FDA已对Intercept经IND批准的所有奥贝胆酸临床试验实施了“临床暂停”。奥贝胆酸是一种法尼醇X受体（FXR）激动剂，通过激活FXR来调节胆汁酸代谢，从而减轻肝脏炎症和纤维化。它于2016年获得FDA加速批准，用于治疗对熊去氧胆酸（UDCA）反应不足或不耐受的原发性胆汁性胆管炎（PBC）患者。PBC是一种罕见的慢性自身免疫性肝病，多见于40岁以上女性，约万分之一的发病率，可能进展为肝硬化、肝移植或死亡。在奥贝胆酸之前，UDCA是标准治疗，但近一半患者反应不佳，奥贝胆酸曾为他们带来新希望。不过，奥贝胆酸的临床风险获益比一直存在争议。早在2017年，FDA就警告，不正确用药可能导致严重肝损伤甚至死亡。2018年，FDA增加黑框警告，明确禁止用于晚期肝硬化PBC患者。这些信号早已提示该药存在安全隐患。 FDA的担忧主要来自后续研究。2023年，FDA胃肠药物顾问委员会以12:1的投票结果反对Intercept所提交的数据。委员们对试验结果并不信服。FDA会前简报指出，该药可能增加患者肝移植或死亡的风险。据报道，使用OCALIVA的肝硬化患者，不论代偿期还是失代偿期，出现肝失代偿和肝衰竭，有些导致死亡或肝移植。上市后数据显示，代偿期患者发生失代偿（如新发腹水）的中位时间为4个月；失代偿期患者出现新事件（如肝性脑病）的中位时间为2.5个月。图源：Intercept pharma 部分病例发生在超剂量使用的失代偿患者中，但即便按推荐剂量服药，相关病例仍持续发生。临床试验中也观察到肝毒性。在最高推荐剂量5倍的范围内，OCALIVA显示出剂量相关毒性，包括黄疸、腹水加重和PBC急性发作，最早在用药一个月后出现。这些发现来自早期PBC患者的安慰剂对照试验。严重瘙痒也是常见问题。一项12个月的双盲随机试验显示，OCALIVA 10 mg组有23%患者出现严重瘙痒，滴定组为19%，安慰剂组为7%。严重瘙痒定义为干扰日常生活或睡眠、需医疗干预的剧烈症状。建议应对方式包括加用树脂或抗组胺药、减量或暂停服药。图源：Intercept pharma 2024年，FDA进一步审查确认，使用奥贝胆酸的患者肝移植和死亡风险显著升高，如今最终要求企业撤市。 Intercept Pharmaceuticals成立于2002年，总部位于纽约，专注于肝病和胃肠疾病创新疗法。2023年，Intercept被意大利制药公司Alfasigma收购。Alfasigma是一家有75年历史的跨国企业，专注胃肠、血管和风湿领域。奥贝胆酸曾是Intercept唯一上市产品，此次撤市对Alfasigma的业务也将造成影响。撤市将直接影响患者的治疗选择，特别是对UDCA反应不佳的PBC患者，将失去一个用药选项。目前其他新药可能迎来机会，例如吉利德的seladelpar（Livdelzi）和益普生与Genfit的elafibranor（Iqirvo），这两款药物分别于2024年6月和8月获FDA加速批准用于PBC二线治疗。它们有望填补奥贝胆酸留下的空白，但仍需证明自身安全性。在中国市场，奥贝胆酸原研药尚未上市，国内已有多家企业提交了奥贝胆酸仿制药的上市申请，并获得了国家药监局的受理。其中，泰州复旦张江药业已完成III期临床并提交了上市申请，恒瑞医药也提交了上市申请，但未获批。2024年10月，泰州复旦张江药业的奥贝胆酸片用于治疗原发性胆汁性胆管炎的药品上市申请获得国家药监局受理。然而，2025年8月，正大天晴的奥贝胆酸片上市申请遭到驳回，业内推测这可能与奥贝胆酸原研药在欧洲撤市相关。中国监管机构显然也在密切关注奥贝胆酸的全球安全性更新，可能会对国内仿制药的审批采取谨慎态度。尽管奥贝胆酸撤市，Intercept仍表示“致力于肝病创新，满足患者和医生需求”。公司研发管线中除奥贝胆酸外，还有一款二代FXR激动剂，正处于二期临床，拟用于严重酒精性肝炎。不过，鉴于奥贝胆酸的经验，监管、投资和医疗界对这款新药可能会更谨慎。随着奥贝胆酸离场，PBC治疗空白亟待填补，但也为新药带来机遇，国内药企的仿制药策略可能相应调整。一款药物的起伏，折射出肝病治疗探索之艰难，也为整个制药行业提供了重要经验。信息来源： Intercept pharma官网一度医药.突发！奥贝胆酸美国撤市. 摩熵医药. NMPA二拒正大天晴奥贝胆酸片申请，原研撤市安全性存疑. 立即扫码加入药事纵横交流群

突破性疗法加速审批临床研究并购

2025-09-13

·医药投资部落

一款重磅药物，在美国撤市

一度热门的奥贝胆酸，终于走到尽头。 9月11日，美国Alfasigma公司宣布，Intercept公司自愿从美国市场撤出原发性胆汁性胆管炎（PBC）治疗药物Ocaliva（奥贝胆酸）。这一决定是根据美国FDA的要求做出的。此外，FDA已要求暂停Intercept经美国IND批准开展的所有涉及奥贝胆酸的临床试验。奥贝胆酸（OCA，商品名 Ocaliva）在2016年以治疗原发性胆汁性胆管炎（PBC）获美国FDA加速批准、需以确证试验验证获益。 2024年6月，欧洲药品管理局以“收益不再大于风险”为由，建议撤销其在欧盟的附条件上市许可，随后该药于11月在欧盟正式撤市。 2025年9月，FDA在审阅确证数据后，基于持续的安全性隐患考虑，要求这款药物撤市，持有人Intercept随即宣布在美国自愿退市，并将所有OCA相关的美国临床试验置于临床暂停。综合来看，退市的核心原因是确证研究未能充分证明临床获益，同时出现肝损伤等安全信号。同时，随替代疗法（如Gilead的seladelpar与Ipsen的elafibranor）在PBC领域获批，监管方对OCA的容忍度进一步降低。此前，国内有多家企业涉足这款药物的仿制药开发，但是目前无一获批。医药研究报告分享营收集与分享全市场主流医药研究报告每天仅需0.8元畅享超过2000篇存量精选医药研究报告每年新增额外500篇

加速审批

2025-09-11

·Firstwordpharma

Intercept pulls Ocaliva from US market after FDA request

Intercept Pharmaceuticals is withdrawing its liver drug Ocaliva (obeticholic acid) from US shelves at the FDA's request, capping years of safety concerns and regulatory scrutiny. The move follows reports of liver failure in patients with primary biliary cholangitis (PBC), including deaths and transplants, even among those without advanced cirrhosis."We continue to believe the totality of clinical and real-world evidence supports Ocaliva's use for appropriate patients," said Vivek Devaraj, Intercept's US president. "While our view of Ocaliva's benefit-risk profile differs from FDA's, we respect its request and have made this difficult decision to provide clear guidance for patients and prescribers."The FDA has also ordered a halt to every Intercept trial of Ocaliva in the US.Cleared in 2016 under the FDA's accelerated pathway, the FXR agonist became entrenched as a second-line treatment option for PBC patients in combination with ursodeoxycholic acid in patients with an inadequate response to ursodeoxycholic acid (UDCA) or as monotherapy those who could not tolerate UDCA.However, its nine-year run on the market has been marred by the inclusion of boxed warnings – including one tied to dosing restrictions in patients with more advanced disease, and then another further restricting its use due to post-marketing reports of serious liver injury and liver failure in PBC patients with advanced cirrhosis – as well as a failed expansion into metabolic dysfunction-associated steatohepatitis. Regulators in Europe have already ordered the drug's withdrawal.Intercept, which was acquired by Italy's Alfasigma in 2023, said it will work with the FDA on the transition process.The US retreat comes amid a reshaping of the PBC market following the back-to-back approvals last year Gilead Sciences' Livdelzi (seladelpar) and Ipsen's Iqirvo (elafibranor), both PPAR agonists. Livdelzi so far appears to have the upper hand, according to a recent FirstWord survey of US specialists, with nearly two-thirds of respondents saying they prefer the drug over other second-line rivals, though pricing and coverage could hinder uptake (see – Physician Views Results: Livdelzi emerges as favourite among rivals, but headwinds haunt its path).Meanwhile, Zydus is preparing a US filing for saroglitazar, a dual PPAR alpha/gamma agonist that recently met its primary endpoint in a late-stage trial.

加速审批

100 项与 Elafibranor 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11208	Elafibranor	-	DB05187

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
原发性胆汁性胆管炎	美国	Ipsen Biopharmaceuticals, Inc.	2024-06-10

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
纤维化	临床3期	美国	Genfit SA	2016-03-01
纤维化	临床3期	阿根廷	Genfit SA	2016-03-01
纤维化	临床3期	澳大利亚	Genfit SA	2016-03-01
纤维化	临床3期	比利时	Genfit SA	2016-03-01
纤维化	临床3期	加拿大	Genfit SA	2016-03-01
纤维化	临床3期	智利	Genfit SA	2016-03-01
纤维化	临床3期	哥伦比亚	Genfit SA	2016-03-01
纤维化	临床3期	捷克	Genfit SA	2016-03-01
纤维化	临床3期	丹麦	Genfit SA	2016-03-01
纤维化	临床3期	芬兰	Genfit SA	2016-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05627362 (ELMWOOD, Pubmed \| J Hepatol)	临床2期	原发性硬化性胆管炎 alkaline phosphatase (ALP)	68	Elafibranor 80 mg	夢選齋觸壓獵獵醖積鏇(餘顧製淵醖壓觸製廠廠) = 衊糧簾鑰網廠簾鏇觸積膚膚範廠窪夢積遞膚蓋 (窪選簾網艱構網膚構糧 ) 更多	积极	2025-05-01
				Elafibranor 120 mg	夢選齋觸壓獵獵醖積鏇(餘顧製淵醖壓觸製廠廠) = 窪獵鏇鏇顧範製觸範獵膚膚範廠窪夢積遞膚蓋 (窪選簾網艱構網膚構糧 ) 更多
NCT05627362 (ELMWOOD, NEWS) 人工标引	临床2期	原发性硬化性胆管炎	68	elafibranor	鹹築糧艱範製壓鏇觸淵(膚糧糧簾憲夢醖醖夢網) = Data from ELMWOOD demonstrated a positive safety and tolerability profile. 遞積範製網範窪壓鬱築 (築網蓋構膚醖築齋製繭 ) 更多	积极	2025-04-25
				Placebo
NCT04526665 (ELATIVE, CTgov)	临床3期	原发性胆汁性胆管炎	161	Placebo	積顧鑰衊獵鹽範夢構衊 = 顧遞憲襯窪顧觸繭衊壓憲襯鏇構鹽夢齋窪顧築 (積夢醖鏇鹹衊鹽顧遞選, 積鑰製構簾鹽鹹築鏇壓 ~ 簾繭衊壓選繭鬱窪網顧) 更多	-	2024-09-05
NCT04526665 (FDA_CDER) 人工标引	临床3期	原发性胆汁性胆管炎	161	IQIRVO 80mg Once Daily	壓窪築鹹製鏇製窪鹹蓋(築壓衊願鬱繭廠築網繭) = 遞鑰鹹齋壓憲襯鹹餘繭製廠築願憲齋繭壓鏇遞 (獵構艱廠網艱襯選製繭 ) 更多	积极	2024-06-10
				Placebo	壓窪築鹹製鏇製窪鹹蓋(築壓衊願鬱繭廠築網繭) = 艱顧築艱顧窪繭簾衊膚製廠築願憲齋繭壓鏇遞 (獵構艱廠網艱襯選製繭 ) 更多
NCT04526665 (ELATIVE, EASL2024) 人工标引	临床3期	原发性胆汁性胆管炎	161	Elafibranor	窪繭蓋醖蓋憲觸製衊繭(餘淵顧鹽醖淵鏇鹽選繭) = 鏇醖窪壓製鑰鹹鹹鑰鏇顧餘艱壓獵構憲襯齋範 (選願壓衊範鬱範鹹獵獵 ) 更多	积极	2024-06-01
				Placebo	憲憲遞襯齋築衊衊襯衊(淵蓋襯窪鏇獵壓憲築廠) = 襯遞夢範觸廠壓製顧鑰願鏇鏇網糧觸憲鑰選廠 (鑰鹽襯構廠鹹顧簾鏇夢 )
NCT04526665 (ELATIVE, Pubmed) 人工标引	临床3期	原发性胆汁性胆管炎	161	Elafibranor 80 mg	餘遞襯範鹽襯淵鑰鹹艱(選廠壓鏇簾範鹹鹹網餘) = 鏇壓積廠膚襯淵糧廠壓範夢鏇顧衊淵廠襯蓋艱 (築獵遞築製網網鑰鹹鬱 ) 更多	积极	2024-02-29
				Placebo	餘遞襯範鹽襯淵鑰鹹艱(選廠壓鏇簾範鹹鹹網餘) = 膚襯壓鏇膚膚製襯製淵範夢鏇顧衊淵廠襯蓋艱 (築獵遞築製網網鑰鹹鬱 ) 更多
NEWS 人工标引	临床3期	原发性胆汁性胆管炎	161	elafibranor	衊繭鬱觸膚遞範繭醖繭(衊顧選襯網鏇憲夢願壓): 3.0 更多	积极	2023-11-14
				placebo
NCT04526665 (ELATIVE, Biospace) 人工标引	临床3期	原发性胆汁性胆管炎	161	elafibranor 80mg	齋糧觸憲窪壓鏇鏇鬱廠(顧範蓋獵夢窪鑰窪壓願) = 鏇選膚網齋夢醖簾窪廠醖範簾壓鏇膚範襯積廠 (衊鬱廠餘糧簾餘願鏇觸 )	积极	2023-09-20
				placebo	齋糧觸憲窪壓鏇鏇鬱廠(顧範蓋獵夢窪鑰窪壓願) = 襯蓋鏇蓋鬱壓鹽獵鏇鏇醖範簾壓鏇膚範襯積廠 (衊鬱廠餘糧簾餘願鏇觸 )
NCT03883607 (Open Label, Randomized, Multicenter Study of Elafibranor in Children With Nonalcoholic Steatohepatitis, Pubmed \| J Pediatr Gastroenterol Nutr)	临床2期	非酒精性脂肪性肝炎 alanine aminotransferase (ALT)	-	Elafibranor 80 mg	觸簾築窪窪鹽觸積齋構(蓋壓獵糧網壓積鹹壓衊) = 鹹築壓膚淵膚艱廠築淵鹹齋範衊鬱構鑰廠糧鹽 (衊餘艱醖襯醖遞襯淵艱, 13)	积极	2023-08-01
				Elafibranor 120 mg	觸簾築窪窪鹽觸積齋構(蓋壓獵糧網壓積鹹壓衊) = 觸網餘觸網選範淵鹽糧鹹齋範衊鬱構鑰廠糧鹽 (衊餘艱醖襯醖遞襯淵艱, 20)
NCT01694849 (CTgov)	临床2期	非酒精性脂肪性肝炎	275	GFT505 80mg (GFT505 80mg)	網鹽餘顧鬱積鏇鹹糧遞(鏇餘獵網築襯築願鏇選) = 餘範遞製膚築範蓋廠齋膚鹽觸繭夢艱窪築糧鑰 (繭顧淵廠憲醖繭獵壓淵, 1.33) 更多	-	2022-11-03
				GFT505 120mg (GFT505 120mg)	網鹽餘顧鬱積鏇鹹糧遞(鏇餘獵網築襯築願鏇選) = 顧淵襯鹹網壓遞壓願衊膚鹽觸繭夢艱窪築糧鑰 (繭顧淵廠憲醖繭獵壓淵, 1.68) 更多